Terence Law
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Terence Law.
Therapeutic Drug Monitoring | 2002
Erin Connor; Masayuki Sakamoto; Kenichi Fujikawa; Terence Law; Nader Rifai
The authors developed an HPLC assay for determining blood sirolimus concentration using a relatively simple solid-phase extraction and UV detection. The retention times of sirolimus and the internal standard, 32-desmethoxyrapamycin, are 8.7 and 9.3 minutes, respectively. The assay possesses linearity up to 200 ng/mL, sensitivity to 2.0 ng/mL, and day-to-day reproducibility of 8.8, 9.8, 6.1, and 6.4% at sirolimus concentrations of 6, 10, 20, and 30 ng/mL, respectively. A patient correlation study using this HPLC method and an established LC/MS/MS assay revealed a slope of 0.982 and intercept of −0.021 ng/mL and a correlation coefficient of 0.99 (n = 37). Of the 31 different drugs tested none interfered with the measurement of the drug of interest, and a recovery study gave an overall mean recovery of 101.8%. The authors conclude that the method described here is suited for the therapeutic monitoring of blood sirolimus concentration.
Therapeutic Drug Monitoring | 1997
Nader Rifai; Mahmoud Lafi; Masayuki Sakamoto; Terence Law
The authors developed a high performance liquid chromatography assay for the determination of plasma ketoprofen concentration using a single-step extraction, a short chromatographic separation of 3 min, and a sample volume of 50 microliters. The assay possessed linearity up to 500 mg/l, sensitivity down to at least 1 mg/l, average recovery of 100.1%, and run-to-run precision (n = 20) of 4.6% at a level of 10 mg/l and 2.2% at a level of 40 mg/l. Furthermore, the assay was free of interference from 51 prescription and over-the-counter medications. The authors conclude that the method described here is ideally suited for the determination of ketoprofen concentration in a clinical laboratory setting for the purpose of therapeutic monitoring and assessment of toxicity.
Therapeutic Drug Monitoring | 1995
Elizabeth Bonagura; Terence Law; Nader Rifai
Summary Immunoassays for digoxin measurement have long had the problem of low specificity. Antisera used in these assays may not only measure digoxin and the active metabolites but also cross-react with the noncardioactive metabolites and digoxin-like immunoreactive factors (DLIFs). In this study, we describe the analytical performance of the newly introduced Roche-TDM ONLINE digoxin assay on the COBAS FARA II centrifugal analyzer. The assay possessed linearity up to 5.0 ng/ml, sensitivity of 0.19 ng/ml, average recovery of 100.4%, and day-to-day variability of <6%. The assay demonstrated no cross-reactivity with DLIFs or spironolactone and its metabolites and negligible reactivity with the digoxin noncardioactive metabolites. In addition, the immunoreactivity of the digoxin active metabolites reflected their cardioactivity. We conclude that the Roche-TDM ONLINE digoxin assay is highly specific and precise and suitable for the therapeutic monitoring of this drug.
Clinical Chemistry | 1998
Nader Rifai; Elizabeth Iannotti; Kristen M. DeAngelis; Terence Law
Clinical Chemistry | 1997
Neil S. Harris; Vartouhi Galpchian; Jennifer Thomas; Elizabeth Iannotti; Terence Law; Nader Rifai
Clinical Chemistry | 1998
Nader Rifai; Thomas G. Cole; Elizabeth Iannotti; Terence Law; Michael Macke; Richard Miller; Dennis Dowd; Donald A. Wiebe
Clinical Chemistry | 2000
Harry H. Yu; Rana Joubran; Muhamad Asmi; Terence Law; Anthony Spencer; Muhidien Jouma; Nader Rifai
Clinical Chemistry | 1996
Nader Rifai; Masayuki Sakamoto; Terence Law; Vartouhi Galpchian; Neil Harris; Andrew A. Colin
American Journal of Clinical Pathology | 1995
Neil Harris; Mary E. Chmil; Terence Law; Nader Rifai
Archive | 1998
Nader Rifai; Elizabeth Iannotti; Kristen M. DeAngelis; Terence Law